RE:Cancer phase 1 expectations Yes, phase I is about safety. But if TH-1902 doesn't show efficacy in this population it won't show efficacy in a less treated population. Sortilin expression increases as the disease progresses. This is how TH-1902 is very different from other treatments.
jeffm34 wrote: I think we have to temper expectations of efficacy in the phase 1 trial. They are enrolling patients with no other options left so their prognosis is very poor. Success in this trial will be if TH1902 is no more toxic than docetaxel alone. If there are no significant signs of efficacy, it is not necessarily a failure. If there is significant efficacy in this patient population it would be pretty amazing to say the least.
The phase 1 study will comprise dose-escalation and dose-expansion portions.7 Patients have to have recurrent advanced solid tumors, have relapsed on or be refractory to standard chemotherapy, surgery, and radiation, and have no effective alternative treatment options to be eligible for the first-in-human study of TH1902.